A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 286 participants.
Also called NCT05342623
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 286 participants
- Sponsor
- Registry
-
NCT05342623
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT05342623. Randomized; double masking; primary purpose treatment. Start 2022-05-17 (actual); primary completion 2024-02-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Condition
- Chronic Kidney Diseases
- Condition
- Pruritus
- Intervention (Drug)
- Difelikefalin 1 mg Oral Tablet
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Cara Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct05342623- Content hash
a2b9b5d3bbb9e561705cd6215b5569922261daaf2673b73ea15aa7ea1a0ab51d